Last reviewed · How we verify

Proglycem (DIAZOXIDE)

Teva Branded Pharm · FDA-approved approved Small molecule Quality 55/100

Proglycem works by blocking the ATP-sensitive potassium channel, which helps to increase blood sugar levels and reduce insulin secretion.

Proglycem (Diazoxide) is a small molecule diazoxide drug that targets the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel. Originally developed and currently owned by Teva Branded Pharm, it was FDA-approved in 1973 for various indications including hyperinsulinism, hypertensive emergencies, and insulinoma. As an off-patent medication, Proglycem is available as a generic from multiple manufacturers. Key safety considerations include its potential to cause hypotension and electrolyte imbalances. Proglycem's commercial status allows for generic competition.

At a glance

Generic nameDIAZOXIDE
SponsorTeva Branded Pharm
Drug classdiazoxide
TargetSulfonylurea receptor 1, Kir6.2
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved
First approval1973

Mechanism of action

Imagine your cells have a special gate that controls how much sugar and insulin they let in. Proglycem blocks this gate, making it harder for insulin to enter the cells and causing blood sugar levels to rise. This can be helpful for people with conditions like hyperinsulinism, where their cells are producing too much insulin.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: